Vita Life Sciences Valuation
Is VLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VLS (A$2.06) is trading below our estimate of fair value (A$11.81)
Significantly Below Fair Value: VLS is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VLS?
Key metric: As VLS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is VLS's PE Ratio? | |
|---|---|
| PE Ratio | 12.3x |
| Earnings | AU$9.39m |
| Market Cap | AU$117.69m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 7.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does VLS's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.8x | ||
VIT Vitura Health | 16.1x | n/a | AU$56.4m |
ECS ECS Botanics Holdings | 11.4x | n/a | AU$21.9m |
NEU Neuren Pharmaceuticals | 13.5x | -9.9% | AU$1.6b |
EZZ EZZ Life Science Holdings | 18.2x | 17.9% | AU$127.5m |
VLS Vita Life Sciences | 12.3x | n/a | AU$117.7m |
Price-To-Earnings vs Peers: VLS is good value based on its Price-To-Earnings Ratio (12.3x) compared to the peer average (14.8x).
Price to Earnings Ratio vs Industry
How does VLS's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 27 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 27 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: VLS is good value based on its Price-To-Earnings Ratio (12.3x) compared to the Global Pharmaceuticals industry average (22.8x).
Price to Earnings Ratio vs Fair Ratio
What is VLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 12.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VLS's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Little Green Pharma
AU$39.2m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.13
7D
0%
1Y
6.1%
AVITA Medical
US$339.9m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.92
7D
2.3%
1Y
25.0%
AVITA Medical
US$342.3m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.97
7D
0.3%
1Y
19.6%